Agency Information Collection Activities; Proposed Collection; Comment Request; Requests for Inspection Under the Inspection by Accredited Persons Program, 31692-31693 [E8-12297]
Download as PDF
31692
Federal Register / Vol. 73, No. 107 / Tuesday, June 3, 2008 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Public Meeting of the President’s
Council on Bioethics
Department of Health and
Human Services, Office of Public Health
and Science, The President’s Council on
Bioethics.
ACTION: Notice.
AGENCY:
SUMMARY: The President’s Council on
Bioethics (Edmund D. Pellegrino, MD,
Chairman) will hold its thirty-third
meeting, at which it will discuss its
projected White Paper on newborn
screening and hear and discuss
presentations on the ethics of health
care reform. Subjects discussed at past
Council meetings (although not on the
agenda for the June 2008 meeting)
include: therapeutic and reproductive
cloning, assisted reproduction,
reproductive genetics, neuroscience,
aging retardation, organ transplantation,
personalized medicine, and lifespan
extension. Publications issued by the
Council to date include: Human Cloning
and Human Dignity: An Ethical Inquiry
(July 2002); Beyond Therapy:
Biotechnology and the Pursuit of
Happiness (October 2003); Being
Human: Readings from the President’s
Council on Bioethics (December 2003);
Monitoring Stem Cell Research (January
2004), Reproduction and Responsibility:
The Regulation of New Biotechnologies
(March 2004), Alternative Sources of
Human Pluripotent Stem Cells: A White
Paper (May 2005), Taking Care: Ethical
Caregiving in Our Aging Society
(September 2005), and Human Dignity
and Bioethics: Essays Commissioned by
the President’s Council on Bioethics
(March 2008). Reports on controversies
in the determination of death and on
organ donation, procurement,
allocation, and transplantation are
forthcoming.
The meeting will take place
Thursday, June 26, 2008, from 9 a.m. to
5 p.m. (CT); and Friday, June 27, 2008,
from 9 a.m. to 11:15 a.m. (CT).
ADDRESSES: Courtyard Marriott
Magnificent Mile, 165 East Ontario
Street, Chicago, IL 60611. Phone 312–
573–0800.
FOR FURTHER INFORMATION CONTACT: Ms.
Diane M. Gianelli, Director of
Communications, The President’s
Council on Bioethics, 1425 New York
Avenue, NW., Suite C100, Washington,
DC 20005. Telephone: 202/296–4669; email: info@bioethics.gov; Web site:
https://www.bioethics.gov.
SUPPLEMENTARY INFORMATION: The
meeting agenda will be posted at
ebenthall on PRODPC60 with NOTICES
DATES:
VerDate Aug<31>2005
14:18 Jun 02, 2008
Jkt 214001
https://www.bioethics.gov. The Council
encourages public input, either in
person or in writing. At this meeting,
interested members of the public may
address the Council, beginning at 11
a.m. (CT), on Friday, June 27. Comments
are limited to no more than five minutes
per speaker or organization. As a
courtesy, please inform Ms. Diane M.
Gianelli, Director of Communications,
in advance of your intention to make a
public statement, and give your name
and affiliation. To submit a written
statement, mail or e-mail it to Ms.
Gianelli at one of her contact addresses
given above.
Dated: May 22, 2008.
F. Daniel Davis,
Executive Director, The President’s Council
on Bioethics.
[FR Doc. E8–12344 Filed 6–2–08; 8:45 am]
BILLING CODE 4154–06–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0313]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Requests for
Inspection Under the Inspection by
Accredited Persons Program
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the eligibility criteria and the process to
be followed by establishments when
requesting FDA’s approval to have an
accredited third party conduct a quality
systems regulation inspection of their
establishment instead of FDA, under the
new inspections by the Accredited
Persons Program.
DATES: Submit written or electronic
comments on the collection of
information by August 4, 2008.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, M20852. All comments
should be identified with the docket
number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301 827–
1472.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Requests for Inspection Under the
Inspection by Accredited Persons
Program—21 U.S.C. 374(g) (OMB
Control Number 0910–0569)—Extension
Section 201 of the Medical Device
User Fee and Modernization Act of
2002, (Public Law 107–250), amended
section 704 of the Federal Food, Drug,
E:\FR\FM\03JNN1.SGM
03JNN1
31693
Federal Register / Vol. 73, No. 107 / Tuesday, June 3, 2008 / Notices
and Cosmetic Act by adding subsection
(g) (21 U.S.C. 374 (g)). This amendment
authorized FDA to establish a voluntary
third party inspection program
applicable to manufacturers of class II or
class III medical devices who meet
certain eligibility criteria. On September
15, 2005, FDA issued a guidance
entitled, ‘‘Requests for Inspection by an
Accredited Person under the Inspection
by Accredited Persons Program
Authorized by Section 201 of the
Medical Device User Fee and
Modernization Act 2002,’’ https://
www.fda.gov/cdrh/comp/guidance/
1532.html. This guidance describes the
eligibility criteria and the process for
establishments to follow when
requesting FDA’s approval to have an
accredited person (AP) conduct a
quality system regulation inspection of
their establishment under the new
inspection by the Accredited Persons
Program (AP program) instead of FDA.
The AP program applies to
manufacturers who currently market
their medical devices in the United
States and who also market or plan to
market their devices in foreign
countries. Such manufacturers may
need current inspections of their
establishments to operate in global
commerce.
In order to meet the eligibility criteria
for requesting FDA approval to have an
AP conduct a quality system regulations
inspection of their establishment
instead of FDA, applicants must submit
a request with certain information. The
following information must be
submitted, which shows that the
applicant:
(1) ‘‘Manufactures, prepares,
propagates, compounds, or processes’’
class II or class III medical devices,
(2) Markets at least one of the devices
in the United States,
(3) Markets or intends to market at
least one of the devices in one or more
foreign countries when one or both of
the following two conditions are met:
(a) One of the foreign countries
certifies, accredits, or otherwise
recognizes the selected AP applicant as
a person authorized to conduct
inspections of device establishments, or
(b) A statement that the law of a
country where the applicant markets or
intends to market the device recognizes
an inspection conducted by FDA or an
AP.
(4) Provided the most recent
inspection performed by FDA, or by an
AP under the AP program and
inspection was classified by FDA as
either ‘‘No Action Indicated’’ or
‘‘Voluntary Action Indicated’’ and,
(5) Provided notice advising FDA of
their intent to use an AP, and
identifying the AP applicant selected.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 U.S.C. Section:
No. of
Respondents
374(g)
ebenthall on PRODPC60 with NOTICES
1 There
Annual Frequency
per Response
100
Total Annual
Responses
1
Hours per
Response
100
Total Hours
15
1,500
are no capital costs or operating and maintenance costs associated with this collection of information.
There are approximately 8,000 foreign
and 10,000 domestic manufacturers of
medical devices. Approximately 5,000
of these firms only manufacture class I
devices and are, therefore, not eligible
for the AP program. In addition, 40
percent of the domestic firms do not
export devices and therefore are not
eligible to participate in the AP
program. Further, 10 to 15 percent of the
firms are not eligible due to the results
of their previous inspection. FDA
estimates there are 4,000 domestic
manufacturers and 4,000 foreign
manufacturers that are eligible for
inclusion under the AP program. Based
on communications with industry, FDA
estimates that on an annual basis
approximately 100 of these
manufacturers may submit a request to
use an AP in any given year.
Please note that on January 15, 2008,
the FDA Division of Dockets
Management Web site transitioned to
the Federal Dockets Management
System (FDMS). FDMS is a
Government-wide, electronic docket
management system. Electronic
comments or submissions will be
accepted by FDA only through FDMS at
https://www.regulations.gov.
VerDate Aug<31>2005
14:18 Jun 02, 2008
Jkt 214001
Dated: May 27, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–12297 Filed 6–2–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0312]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Extralabel Drug
Use in Animals
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
PO 00000
Frm 00021
Fmt 4703
Sfmt 4703
public comment in response to the
notice. This notice solicits comments on
the reporting requirements associated
with extralabel drug use in animals.
DATES: Submit written or electronic
comments on the collection of
information by August 4, 2008.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1472.
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
SUPPLEMENTARY INFORMATION:
E:\FR\FM\03JNN1.SGM
03JNN1
Agencies
[Federal Register Volume 73, Number 107 (Tuesday, June 3, 2008)]
[Notices]
[Pages 31692-31693]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-12297]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0313]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Requests for Inspection Under the Inspection by
Accredited Persons Program
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the eligibility criteria and
the process to be followed by establishments when requesting FDA's
approval to have an accredited third party conduct a quality systems
regulation inspection of their establishment instead of FDA, under the
new inspections by the Accredited Persons Program.
DATES: Submit written or electronic comments on the collection of
information by August 4, 2008.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, M20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of the
Chief Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301 827-1472.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Requests for Inspection Under the Inspection by Accredited Persons
Program--21 U.S.C. 374(g) (OMB Control Number 0910-0569)--Extension
Section 201 of the Medical Device User Fee and Modernization Act of
2002, (Public Law 107-250), amended section 704 of the Federal Food,
Drug,
[[Page 31693]]
and Cosmetic Act by adding subsection (g) (21 U.S.C. 374 (g)). This
amendment authorized FDA to establish a voluntary third party
inspection program applicable to manufacturers of class II or class III
medical devices who meet certain eligibility criteria. On September 15,
2005, FDA issued a guidance entitled, ``Requests for Inspection by an
Accredited Person under the Inspection by Accredited Persons Program
Authorized by Section 201 of the Medical Device User Fee and
Modernization Act 2002,'' https://www.fda.gov/cdrh/comp/guidance/
1532.html. This guidance describes the eligibility criteria and the
process for establishments to follow when requesting FDA's approval to
have an accredited person (AP) conduct a quality system regulation
inspection of their establishment under the new inspection by the
Accredited Persons Program (AP program) instead of FDA. The AP program
applies to manufacturers who currently market their medical devices in
the United States and who also market or plan to market their devices
in foreign countries. Such manufacturers may need current inspections
of their establishments to operate in global commerce.
In order to meet the eligibility criteria for requesting FDA
approval to have an AP conduct a quality system regulations inspection
of their establishment instead of FDA, applicants must submit a request
with certain information. The following information must be submitted,
which shows that the applicant:
(1) ``Manufactures, prepares, propagates, compounds, or processes''
class II or class III medical devices,
(2) Markets at least one of the devices in the United States,
(3) Markets or intends to market at least one of the devices in one
or more foreign countries when one or both of the following two
conditions are met:
(a) One of the foreign countries certifies, accredits, or otherwise
recognizes the selected AP applicant as a person authorized to conduct
inspections of device establishments, or
(b) A statement that the law of a country where the applicant
markets or intends to market the device recognizes an inspection
conducted by FDA or an AP.
(4) Provided the most recent inspection performed by FDA, or by an
AP under the AP program and inspection was classified by FDA as either
``No Action Indicated'' or ``Voluntary Action Indicated'' and,
(5) Provided notice advising FDA of their intent to use an AP, and
identifying the AP applicant selected.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
21 U.S.C. No. of Annual Frequency Total Annual Hours per
Section: Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
374(g) 100 1 100 15 1,500
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
There are approximately 8,000 foreign and 10,000 domestic
manufacturers of medical devices. Approximately 5,000 of these firms
only manufacture class I devices and are, therefore, not eligible for
the AP program. In addition, 40 percent of the domestic firms do not
export devices and therefore are not eligible to participate in the AP
program. Further, 10 to 15 percent of the firms are not eligible due to
the results of their previous inspection. FDA estimates there are 4,000
domestic manufacturers and 4,000 foreign manufacturers that are
eligible for inclusion under the AP program. Based on communications
with industry, FDA estimates that on an annual basis approximately 100
of these manufacturers may submit a request to use an AP in any given
year.
Please note that on January 15, 2008, the FDA Division of Dockets
Management Web site transitioned to the Federal Dockets Management
System (FDMS). FDMS is a Government-wide, electronic docket management
system. Electronic comments or submissions will be accepted by FDA only
through FDMS at https://www.regulations.gov.
Dated: May 27, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-12297 Filed 6-2-08; 8:45 am]
BILLING CODE 4160-01-S